Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)

v3.23.2
CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)
$ in Thousands
Jun. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Firm
Investment Holding [Line Items]    
Investment, Basis Spread, Variable Rate 8.25% 7.50%
Tax basis of investments, gross, unrealized appreciation $ 92,500 $ 72,200
Tax basis of investments, gross, unrealized depreciation 92,000 112,000
Tax basis of investments, unrealized appreciation (depreciation), net 500 39,800
Tax basis of investments, cost for income tax purposes 3,100,000 3,000,000
Investment Owned, Cost 3,114,097 3,005,696
Investment Owned, Fair Value $ 3,112,789 $ 2,963,955
1-month LIBOR    
Investment Holding [Line Items]    
Interest rate 5.22% 4.40%
3-month LIBOR    
Investment Holding [Line Items]    
Interest rate 5.55% 4.77%
6-month LIBOR    
Investment Holding [Line Items]    
Interest rate 5.76% 5.14%
1-month SOFR    
Investment Holding [Line Items]    
Interest rate 5.07%  
3-month SOFR    
Investment Holding [Line Items]    
Interest rate 5.00%  
6-month SOFR    
Investment Holding [Line Items]    
Interest rate 4.78%  
Common Stock | Fair Value, Inputs, Level 1 [Member]    
Investment Holding [Line Items]    
Number of publicly traded companies | Firm   43
Warrants | Fair Value, Inputs, Level 1 [Member]    
Investment Holding [Line Items]    
Number of publicly traded companies | Firm   27
Biotechnology Tools    
Investment Holding [Line Items]    
Investment Owned, Fair Value $ 33,465 $ 32,825
Media/Content/Info    
Investment Holding [Line Items]    
Investment Owned, Fair Value 11,542 35
Surgical Devices    
Investment Holding [Line Items]    
Investment Owned, Fair Value 731 3,038
Consumer & Business Products    
Investment Holding [Line Items]    
Investment Owned, Fair Value 1,294 2,821
Communications & Networking    
Investment Holding [Line Items]    
Investment Owned, Fair Value 105,343 101,833
Drug Delivery    
Investment Holding [Line Items]    
Investment Owned, Fair Value 23 90
Drug Discovery & Development    
Investment Holding [Line Items]    
Investment Owned, Fair Value 1,137,725 1,150,707
Medical Devices & Equipment    
Investment Holding [Line Items]    
Investment Owned, Fair Value 1,052 1,834
Information Services    
Investment Holding [Line Items]    
Investment Owned, Fair Value 73,306 60,759
Semiconductors    
Investment Holding [Line Items]    
Investment Owned, Fair Value 1,188 21,921
Healthcare Services Other    
Investment Holding [Line Items]    
Investment Owned, Fair Value 220,673 198,763
Manufacturing Technology    
Investment Holding [Line Items]    
Investment Owned, Fair Value 49,596 46,109
Diversified Financial Services    
Investment Holding [Line Items]    
Investment Owned, Fair Value 94,077 68,569
Sustainable And Renewable Technology    
Investment Holding [Line Items]    
Investment Owned, Fair Value 11,333 15,486
Software    
Investment Holding [Line Items]    
Investment Owned, Fair Value 891,438 798,264
Consumer And Business Services [Member]    
Investment Holding [Line Items]    
Investment Owned, Fair Value 459,276 439,384
Electronics & Computer Hardware    
Investment Holding [Line Items]    
Investment Owned, Fair Value 20,727 21,517
Phathom Pharmaceuticals, Inc. | Royalty Contract    
Investment Holding [Line Items]    
Investment Owned, Cost 4,600 4,600
Investment Owned, Fair Value 3,100 3,400
Black Crow AI, Inc. affiliates | Promissory Notes [Member]    
Investment Holding [Line Items]    
Investment Owned, Balance, Principal Amount 2,400 3,000
Senior Secured    
Investment Holding [Line Items]    
Investment Owned, Fair Value $ 2,878,923 $ 2,741,388